Hantz Financial Services, Inc. Arcus Biosciences, Inc. Transaction History
Hantz Financial Services, Inc.
- $6.19 Billion
- Q2 2025
A detailed history of Hantz Financial Services, Inc. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 283 shares of RCUS stock, worth $4,259. This represents 0.0% of its overall portfolio holdings.
Number of Shares
283
Previous 11
2472.73%
Holding current value
$4,259
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RCUS
# of Institutions
208Shares Held
67MCall Options Held
3.18MPut Options Held
167K-
Black Rock Inc. New York, NY9.76MShares$147 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.56MShares$98.7 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$89.8 Million0.11% of portfolio
-
Woodline Partners LP San Francisco, CA4MShares$60.2 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$55.5 Million1.03% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.09B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...